Bioxydyn offers imaging biomarkers for respiratory diseases such as cystic fibrosis, asthma, pulmonary hypertension, interstitial disease and COPD. We are the world leaders in delivering oxygen-enhanced MRI (OE-MRI) for imaging lung function.
OE-MRI is a non-invasive and non-ionising imaging method that uses oxygen as an MR imaging agent, which is delivered to the patient in the scanner. OE-MRI can be deployed on most hospital MRI scanners.
Lung OE-MRI monitors the delivery of oxygen to the patient's lungs and the acquired quantitative imaging biomarkers relate to regional lung ventilation and gas diffusion in diseases such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma.
The images show ventilation defects in an adult cystic fibrosis patient. Blue regions show parts of the lung that are receiving oxygen; the black regions of the lung represent areas with no detectable oxygen delivery.
Bioxydyn is also a leader in dynamic contrast-enhanced MRI (DCE-MRI) in the lung, providing information on lung perfusion and other microvascular function, including endothelial permeability and leakage space in diseases such as pulmonary embolism, asthma, pulmonary hypertension, interstitial disease and COPD.
Bioxydyn also provides imaging biomarkers of lung ventilation based on the motion of the lung over time. These measurements provide ventilation-weighted imaging in a short scan without administration of gases or contrast agents.
Martini K, Gygax CM, Benden C, Morgan AR, Parker GJM, Frauenfelder T, Volumetric dynamic oxygen-enhanced MRI (OE-MRI): comparison with CT Brody score and lung function in cystic fibrosis patients. Eur Radiol. 2018 Oct;28(10):4037-4047.
Morgan AR, Parker GJ, Roberts C, Buonaccorsi GA, Maguire NC, Hubbard Cristinacce PL, Singh D, Vestbo J, Bjermer L, Jögi J, Taib Z, Sarv J, Bruijnzeel PL, Olsson LE, Bondesson E, Nihlén U, McGrath DM, Young SS, Waterton JC, Nordenmark LH, Feasibility assessment of using oxygen-enhanced magnetic resonance imaging for evaluating the effect of pharmacological treatment in COPD. Eur J Radiol. 2014 Nov;83(11):2093-101.
Kershaw LE, Naish JH, McGrath DM, Waterton JC, Parker GJ, Measurement of arterial plasma oxygenation in dynamic oxygen-enhanced MRI. Magn Reson Med. 2010 Dec;64(6):1838-42.
Naish JH, Kershaw LE, Buckley DL, Jackson A, Waterton JC, Parker GJ, Modeling of contrast agent kinetics in the lung using T1-weighted dynamic contrast-enhanced MRI. Magn Reson Med. 2009 Jun;61(6):1507-14.
Zhang WJ, Niven RM, Young SS, Liu YZ, Parker GJ, Naish JH, T1-weighted Dynamic Contrast-enhanced MR Imaging of the Lung in Asthma: Semiquantitative Analysis for the Assessment of Contrast Agent Kinetic Characteristics. Radiology. 2016 Mar;278(3):906-16.
Zhang WJ, Niven RM, Young SS, Liu YZ, Parker GJ, Naish JH, Dynamic oxygen-enhanced magnetic resonance imaging of the lung in asthma -- initial experience. Eur J Radiol. 2015 Feb;84(2):318-26.
Alamidi DF, Kindvall SS, Hubbard Cristinacce PL, McGrath DM, Young SS, Naish JH, Waterton JC, Wollmer P, Diaz S, Olsson M, Hockings PD, Lagerstrand KM, Parker GJ, Olsson LE, T1 Relaxation Time in Lungs of Asymptomatic Smokers. PLoS One. 2016;11(3):e0149760.
Tiddens HA, Stick SM, Wild JM, Ciet P, Parker GJ, Koch A, Vogel-Claussen J, Respiratory tract exacerbations revisited: ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. Pediatr Pulmonol. 2015 Oct;50 Suppl 40:S57-65.